Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIMEDX GROUP, INC.

(MDXG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

11/22/2021 | 08:03am EST

Item 7.01 Regulation FD

On Monday, November 22, 2021, Timothy R. Wright, MiMedx Chief Executive Officer, and Rohit Kashyap, Ph.D., MiMedx Chief Commercial Officer, are expected to present at the Piper Sandler 33rd Annual Healthcare Conference on behalf of MiMedx Group, Inc. (the "Company" or "MiMedx"), beginning at 10:00 a.m. Eastern Time. A copy of the presentation materials they will use are attached hereto as Exhibit 99.1 and are incorporated herein for reference. The presentation materials shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section and shall only be incorporated by reference into another filing under the Exchange Act or Securities Act of 1933 if such subsequent filing specifically references this Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.
Exhibit No.              Description of Exhibit
99.1                       Slide Presentation dated November 22, 2021
                         The cover page from this Current Report on Form 8-K, formatted in Inline
104                      XBRL.

© Edgar Online, source Glimpses

All news about MIMEDX GROUP, INC.
01/10MIMEDX GROUP, INC. : Results of Operations and Financial Condition, Regulation FD Disclosu..
AQ
01/10MIMEDX Outlines Key Strategic Milestones for 2022
AQ
01/10MiMedx Group, Inc. Provides Revenue Guidance for the Financial Year 2022
CI
01/04MIMEDX to Participate at the H.C. Wainwright BioConnect Virtual Conference
AQ
2021MIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
2021MiMedx Lifts Adjusted Net Sales Outlook for FY21
MT
2021MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day
AQ
2021Mimedx Group, Inc. to Provide New Details About Near- and Long-Term Growth Opportunitie..
CI
2021MIMEDX Announces Speakers for December 7 Investor Day
AQ
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
Financials (USD)
Sales 2021 255 M - -
Net income 2021 -19,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -25,1x
Yield 2021 -
Capitalization 474 M 474 M -
Capi. / Sales 2021 1,86x
Capi. / Sales 2022 1,77x
Nbr of Employees 735
Free-Float 96,6%
Chart MIMEDX GROUP, INC.
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 4,27 $
Average target price 14,17 $
Spread / Average Target 232%
EPS Revisions
Managers and Directors
Timothy R. Wright Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Robert Benjamin Stein Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-29.30%474
GILEAD SCIENCES, INC.-7.35%84 470
REGENERON PHARMACEUTICALS-4.16%63 282
MODERNA, INC.-41.48%62 828
VERTEX PHARMACEUTICALS3.93%57 608
LONZA GROUP AG-20.54%48 784